ALVAL — Valbiotis SA Share News
0.000.00%
Last trade - 00:00- €18.60m
- €11.17m
- €0.91m
French and Benelux stocks-Factors to watch
Brief: Valbiotis FY Operating Profit Eur -9.5 Mln
Brief: Valbiotis Launches Capital Increase For Gross Amount Of Nearly EUR 6.9 Mln
Brief: Valbiotis Signs Strategic Agreements With Two Pharmaceutical Groups
Brief: Valbiotis Announces Partnership With Asetys
Brief: Valbiotis, Nestle Health Science Agree To Terminate Licensing and Supply Agreement
Brief: Valbiotis To Launch Natural Dietary Supplement For Management Of Hypercholesterolemia On French Market
Brief: Valbiotis Sets Out 2024 Commercial and Clinical Roadmap
Brief: Valbiotis Announces Success Of Its 15 Million Euros Capital Increase
Brief: Valbiotis Has Received FDA Approval For NDI Status
Brief: Valbiotis Announces The Launch Of A Capital Increase
Brief: Valbiotis Announces Totum 63 Clinical Study Success
French and Benelux stocks-Factors to watch
Brief: Valbiotis H1 Net Loss Narrows To 1.9 Million Euros
Brief: Valbiotis Presents Full Results Of Phase II/III REVERSE-IT Study
Hold!! French And Benelux Stocks: Factors to watch
Brief: Valbiotis Announces Success Of Reverse-It Phase Ii/Iii Clinical Study For Totum 63
Brief: Valbiotis FY Turnover Up At €785.000 Euros
Brief: Valbiotis Announces Last Visit Of Last Patient In Phase II/III Reverse-It Study